(INDV) Indivior Pharmaceuticals Inc Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(INDV) Indivior Pharmaceuticals Inc Complete Analysis Pack
Unlock Strategic Clarity
This Indivior Pharmaceuticals Inc 4P's Marketing Mix Analysis explains the company’s product offerings (buprenorphine-based treatments), their clinical use for opioid dependence, and how price, place, and promotion support uptake. The page shows a real preview/sample of the analysis so you can review style and content—purchase the full version to get the complete ready-to-use report.
Product
SUBLOCADE 100 mg and 300 mg
SUBLOCADE 100 mg and 300 mg is Indivior Pharmaceuticals Inc’s main long-acting opioid use disorder treatment: a once-monthly extended-release buprenorphine injection. The 1-dose-per-month format helps maintenance therapy and can improve adherence versus daily dosing. Its two strengths, 100 mg and 300 mg, let clinicians adjust treatment intensity to patient need.
SUBOXONE Film 2 mg/0.5 mg to 12 mg/3 mg
SUBOXONE Film is a buprenorphine/naloxone sublingual film and a core transmucosal product in Indivior Pharmaceuticals Inc’s portfolio. Its 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg strengths support individualized dosing for opioid dependence treatment. In Indivior Pharmaceuticals Inc’s 2024 reporting, the Product line still anchored revenue, with total net revenue about $1.1 billion.
SUBOXONE Tablet 2 mg/0.5 mg and 8 mg/2 mg
SUBOXONE Tablet 2 mg/0.5 mg and 8 mg/2 mg is buprenorphine/naloxone for opioid dependence, and it stays in Indivior Pharmaceuticals Inc's treatment lineup. The tablet gives prescribers a clear alternative to film, with two strengths that support dose matching in treatment. Its sublingual format is built for supervised use and fits a market where opioid use disorder still drives sustained demand for medication-assisted treatment.
SUBUTEX Tablet 2 mg and 8 mg
SUBUTEX Tablet 2 mg and 8 mg is a buprenorphine-only sublingual prescription option for medication-assisted treatment of opioid dependence. Its 2 mg and 8 mg strengths support dose titration and maintenance use, while the buprenorphine-only profile helps limit exposure to naloxone. In the U.S., about 2.7 million people had opioid use disorder in 2023, so access to proven treatment remains critical.
For Indivior Pharmaceuticals Inc, SUBUTEX fits the Product and Place pillars by offering a clinic- and pharmacy-dispensed MAT option with clear therapeutic positioning. It remains a focused, branded treatment tool in a market where buprenorphine-based care is a core standard.
- Buprenorphine-only sublingual tablet
- Strengths: 2 mg and 8 mg
- Supports MAT pathways
- Targets opioid dependence treatment
Buprenorphine-based prescription portfolio
Indivior Pharmaceuticals Inc’s buprenorphine-based prescription portfolio targets opioid dependence and opioid use disorder, spanning treatment initiation and maintenance. Buprenorphine is used in office-based care, and SAMHSA estimated 2.7 million U.S. adults had OUD in 2023, keeping the addressable need large.
The mix is prescription-only, which supports physician-led access and repeat use in long-term care. Indivior’s portfolio is built around chronic treatment, not one-off sales.
- Focus: opioid dependence and OUD
- Use: initiation plus maintenance
- Channel: prescription-only therapies
Indivior’s OUD Portfolio: SUBLOCADE Drives a $1.1B Product Mix
Indivior Pharmaceuticals Inc’s Product mix centers on SUBLOCADE, SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX, all built for opioid use disorder treatment. The portfolio spans monthly injection and daily sublingual dosing, which supports both initiation and maintenance care. In 2024, Product net revenue was about $1.1 billion.
| Product | Use | Strengths |
|---|---|---|
| SUBLOCADE | Monthly OUD | 100 mg, 300 mg |
What is included in the product
Detailed Word Document
A concise, company-specific breakdown of Indivior Pharmaceuticals Inc’s Product, Price, Place, and Promotion strategy, grounded in real-world pharma market practices.
Editable Excel File
Summarizes Indivior Pharmaceuticals Inc’s 4Ps as a quick pain-point reliever for fast strategic clarity.
Reference Sources
Compiles primary, regulatory, and industry sources to verify Indivior assumptions quickly and speed due diligence with a clear, traceable reference trail.
Place
United States
United States is Indivior Pharmaceuticals Inc’s primary commercial market and the core base for its prescription-drug sales. The company is headquartered in North Chesterfield, Virginia, and its U.S. network supports products like SUBLOCADE and SUBOXONE; Indivior reported about $1.24 billion in net revenue in 2024, with the U.S. driving most of that demand.
United Kingdom
The United Kingdom is one of Indivior's reporting regions and supports international commercialization and corporate activity. In 2025, Indivior reported net revenue of about $1.2 billion, with the U.K. helping broaden geographic exposure beyond the U.S. market. That base adds resilience and supports its global 4P execution.
International markets
Indivior Pharmaceuticals Inc. serves international markets beyond North America and the U.K., widening access for patients with opioid use disorder and broadening its commercial base. In 2024, the Company reported net revenue of about $1.2 billion, showing how global reach supports scale. This wider footprint also reduces reliance on any one market and helps spread demand across regions.
North Chesterfield, Virginia
North Chesterfield, Virginia is Indivior Pharmaceuticals Inc's headquarters, so it anchors corporate, research, and operating oversight. The U.S. base helps direct a business that reported 2025 net revenue of about $1.2 billion, with North America as its core market. For the 4P's mix, this location supports fast U.S. decision-making, compliance, and commercial control.
- U.S. headquarters and management hub
- Supports research and operating oversight
- Backs 2025 revenue near $1.2 billion
Prescription and specialty distribution channels
Indivior Pharmaceuticals Inc sells through prescription channels, so access starts with a healthcare provider and then moves through pharmacies and payer approval. This is built for controlled drugs: specialty handling helps manage dispensing, prior authorization, and patient monitoring, which is critical for long-acting treatments like SUBLOCADE.
- Provider script drives first access
- Payer rules can delay fills
- Specialty pharmacies handle controlled delivery
Indivior’s U.S. Base Powers $1.2B in 2025 Revenue
Place for Indivior Pharmaceuticals Inc is anchored in North Chesterfield, Virginia, with the United States as its main market and the United Kingdom as a key reporting region. That footprint supports U.S. prescription access, specialty pharmacy delivery, and controlled-drug oversight for products like SUBLOCADE and SUBOXONE. Indivior reported about $1.2 billion in 2025 net revenue.
| Place factor | Key data |
|---|---|
| HQ | North Chesterfield, Virginia |
| Main market | United States |
| 2025 net revenue | About $1.2 billion |
Preview Before You Purchase
Indivior Pharmaceuticals Inc Reference Sources
The preview shown here is the exact, full Marketing Mix analysis for Indivior Pharmaceuticals Inc you’ll receive immediately after purchase—no samples or teasers, just the ready-to-use 4P insights and strategic recommendations.
Promotion
Healthcare professional education
Healthcare professional education at Indivior Pharmaceuticals Inc focuses on prescribers and treatment providers, sharing clinical data on opioid dependence therapies and helping drive awareness and appropriate use. In 2024, Indivior reported about $1.1 billion in net revenue, with SUBLOCADE a key revenue driver, so HCP education stays central to demand support and treatment adoption.
Patient support programs
Indivior Pharmaceuticals Inc uses patient support programs to help people start and stay on treatment, with help for access, adherence, and treatment navigation. This supports its branded therapy model by reducing drop-off after prescription and keeping patients connected to care. In FY2025, that matters because every filled script can drive repeat use, which is key for chronic therapy economics.
Disease awareness on opioid dependence
Indivior uses disease awareness to explain opioid use disorder (OUD) and when treatment is needed. SAMHSA estimated 6.1 million U.S. adults had OUD in 2022, so education can push earlier diagnosis and more treatment starts. That matters because CDC reported 107,543 overdose deaths in 2023, making faster care a real need.
Medical congresses and publications
Indivior Pharmaceuticals Inc uses medical congresses and peer-reviewed publications to back its brand with clinical data, which is standard pharma promotion. This channel helps show treatment benefits with trial results, real-world evidence, and expert debate. It matters because trust in prescription drugs depends on proof, not just promotion.
- Clinical data supports messaging
- Congress talks build physician trust
- Publications validate treatment benefit
- Core pharma promotion channel
Digital and field-based engagement
Indivior Pharmaceuticals Inc uses digital tools and field sales to reach healthcare professionals, share product details, and follow up after visits. In 2025, this blend helped keep SUBLOCADE and OPVEE visible in a market where access and repeat contact matter. One channel starts the talk; the other keeps it going.
- Digital tools push product facts fast.
- Field teams deepen HCP trust.
- Follow-up supports market presence.
Indivior’s promotion leans on trust, access, and HCP education
Promotion at Indivior Pharmaceuticals Inc is built around HCP education, patient support, disease awareness, congress data, and field plus digital outreach. With about $1.1 billion in net revenue in 2024 and OUD affecting 6.1 million U.S. adults in 2022, these channels help keep SUBLOCADE and OPVEE visible and drive treatment starts. Trust and access, not mass ads, do the heavy lifting.
| Promotion channel | Why it matters |
|---|---|
| HCP education | Supports prescribing |
| Patient support | Improves start and stay |
| Congress and publications | Builds clinical trust |
Price
Prescription drug pricing
Indivior Pharmaceuticals Inc sells branded prescription medicines, so its pricing sits in the specialty-drug tier rather than generic-drug levels. In FY2025, net revenue was about $1.3 billion, with products like SUBLOCADE priced through payer contracts and pharmacy benefit rules, not a single cash price. Actual patient cost still depends on coverage, deductible status, and dose, so out-of-pocket can vary sharply even for the same medicine.
Commercial and government payer contracts
Indivior Pharmaceuticals Inc depends on commercial and government payer contracts because access to its medicines is set by insurer and public reimbursement rules. Contracting can cut the net realized price through rebates, fees, and prior authorization. Formulary status also matters: when a plan lists a product as preferred, uptake is usually faster, while exclusion or step edits can slow demand.
Copay assistance
Copay assistance can cut Indivior Pharmaceuticals Inc patients' out-of-pocket cost at the pharmacy and help them start therapy faster. In branded drugs, these programs often bring first-fill costs down to $0 to $10, which matters when monthly list prices can run into the hundreds or thousands of dollars.
Patient assistance programs
Patient assistance programs help uninsured and underinsured patients start and stay on long-term treatment, which matters in chronic care where drop-off is costly. In the U.S., 48.5 million people age 12+ had a substance use disorder, so access support is not a side perk; it’s part of demand capture. For Indivior Pharmaceuticals Inc, these programs can cut barriers and lift adherence.
- Supports access and persistence
- Fits chronic treatment needs
- Helps reach underinsured patients
Net pricing by product and market
Indivior Pharmaceuticals’ net price is product-, strength-, and geography-specific, with realized revenue trimmed by rebates, chargebacks, and discounts. In 2025, the company kept pricing tied to access and local competition, especially across SUBLOCADE and SUBOXONE markets, so list price is not the same as net sales.
- Net price differs by product and strength
- Rebates cut realized revenue
- Access drives pricing discipline
- Local competition shapes market price
Indivior’s Net Price Hinges on Access, Not List Price
Indivior Pharmaceuticals Inc prices as a specialty-branded drug maker, so its net price is shaped more by payer access than by list price. In FY2025, net revenue was about $1.3 billion, with SUBLOCADE and SUBOXONE pricing pulled down by rebates, chargebacks, and discounts. Copay help and patient support lower out-of-pocket costs and support adherence.
| Price factor | FY2025 signal |
|---|---|
| Net revenue | About $1.3 billion |
| Pricing model | Contracted specialty pricing |
| Net price | Reduced by rebates and discounts |
| Patient cost | Depends on coverage and deductible |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.